These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 11475788)

  • 41. [Adverse effect-free analgesia. New COX-2 inhibitor is even more selective].
    MMW Fortschr Med; 2003 May; 145(18):54. PubMed ID: 12808824
    [No Abstract]   [Full Text] [Related]  

  • 42. Outcome of peptic ulcer bleeding among users of traditional non-steroidal anti-inflammatory drugs and selective cyclo-oxygenase-2 inhibitors.
    Thomsen RW; Riis A; Christensen S; McLaughlin JK; Sørensen HT
    Aliment Pharmacol Ther; 2006 Nov; 24(10):1431-8. PubMed ID: 17032286
    [TBL] [Abstract][Full Text] [Related]  

  • 43. COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study.
    Nørgård B; Pedersen L; Johnsen SP; Tarone RE; McLaughlin JK; Friis S; Sørensen HT
    Aliment Pharmacol Ther; 2004 Apr; 19(7):817-25. PubMed ID: 15043523
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cardiovascular adverse effects of coxibs.
    Prescrire Int; 2002 Dec; 11(62):181-2. PubMed ID: 12472094
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Erectile dysfunction induced probably by celecoxib.
    Dhikav V; Gupta S; Anand KS
    Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):211-2. PubMed ID: 18236511
    [No Abstract]   [Full Text] [Related]  

  • 46. [Hyperkalemia and celecoxib].
    Rego MJ; Fonseré N; Martí S; Rey-Joly C
    Med Clin (Barc); 2002 Jun; 119(1):36-7. PubMed ID: 12062005
    [No Abstract]   [Full Text] [Related]  

  • 47. The appropriate use of proton-pump inhibitor co-therapy with non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors.
    Lanas A
    Aliment Pharmacol Ther; 2005 Mar; 21 Suppl 1():2-4, 21-4. PubMed ID: 15755265
    [No Abstract]   [Full Text] [Related]  

  • 48. [Selective cyclooxygenase-2 inhibitors and the digestive tract].
    Chaabouni H; Amouri A; Cheikh I; Kchaou M; Ouerghi H; Ben Mami N; Ben Ammar A
    Tunis Med; 2002 Aug; 80(8):427-33. PubMed ID: 12703120
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Current status of the therapeutic uses and actions of the preferential cyclo-oxygenase-2 NSAID, nimesulide.
    Rainsford KD
    Inflammopharmacology; 2006 Aug; 14(3-4):120-37. PubMed ID: 16983492
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nimesulide and COX-2 inhibitors.
    Bakhle YS
    Lancet; 1999 Aug; 354(9180):772. PubMed ID: 10475213
    [No Abstract]   [Full Text] [Related]  

  • 51. Neonatal end-stage renal failure associated with maternal ingestion of cyclo-oxygenase-type-1 selective inhibitor nimesulide as tocolytic.
    Peruzzi L; Gianoglio B; Porcellini MG; Coppo R
    Lancet; 1999 Nov; 354(9190):1615. PubMed ID: 10560684
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The clinical significance of lithium-nonsteroidal anti-inflammatory drug interactions.
    Ragheb M
    J Clin Psychopharmacol; 1990 Oct; 10(5):350-4. PubMed ID: 2258452
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nimesulide and adverse drug reactions: time for a database.
    Khan S
    J Postgrad Med; 2008; 54(3):242. PubMed ID: 18626185
    [No Abstract]   [Full Text] [Related]  

  • 54. Nimesulide-induced hepatitis and acute liver failure.
    Weiss P
    Isr Med Assoc J; 1999 Nov; 1(3):221. PubMed ID: 10731347
    [No Abstract]   [Full Text] [Related]  

  • 55. Oral and intravenous administration of nimesulide in the horse: rational dosage regimen from pharmacokinetic and pharmacodynamic data.
    Villa R; Cagnardi P; Belloli C; Zonca A; Zizzadoro C; Ferro E; Carli S
    Equine Vet J; 2007 Mar; 39(2):136-42. PubMed ID: 17378442
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nimesulide and renal impairment.
    Leone R; Conforti A; Ghiotto E; Moretti U; Valvo E; Velo GP
    Eur J Clin Pharmacol; 1999 Apr; 55(2):151-4. PubMed ID: 10335911
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nimesulide-induced acute hepatitis: evidence from six cases.
    Van Steenbergen W; Peeters P; De Bondt J; Staessen D; Büscher H; Laporta T; Roskams T; Desmet V
    J Hepatol; 1998 Jul; 29(1):135-41. PubMed ID: 9696502
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Economic comparison of nimesulide and diclofenac, and the incidence of adverse events in the treatment of rheumatic disease in Greece.
    Liaropoulos L
    Rheumatology (Oxford); 1999 May; 38 Suppl 1():39-46. PubMed ID: 10369405
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Psoriasiform fixed drug eruption caused by nimesulide.
    Katoulis AC; Bozi E; Kanelleas A; Makris M; Alevizou A; Panagiotides I; Stavrianeas NG
    Clin Exp Dermatol; 2009 Oct; 34(7):e360-1. PubMed ID: 19486051
    [No Abstract]   [Full Text] [Related]  

  • 60. Nimesulide-induced, multifocal, urticarial fixed drug eruption confirmed by oral provocation test.
    Rallis E; Stavropoulou E; Paraskevopoulos I
    Indian J Dermatol Venereol Leprol; 2008; 74(4):403-4. PubMed ID: 18797080
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.